{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:25Z","timestamp":1792684585773,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Kidney transplant recipients with high intrapatient variability (IPV) in tacrolimus (Tac) exposure experience more rejection and reduced graft survival. To understand the underlying pathophysiology of this association, the authors investigated whether patients with high tacrolimus IPV have a more activated immune system than patients with low IPV. In addition, exposure to tacrolimus and mycophenolic acid (MPA) was studied in relation to rejection and graft survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>At the time of patient inclusion (5\u20137 years post-transplantation), the frequency of donor-reactive cells was determined by enzyme-linked immunosorbent assay, and the development of donor-specific anti-Human Leukocyte Antigen antibodies (DSA) was measured by Luminex Single Antigen assay. Tacrolimus IPV was retrospectively calculated between 6 and 12 months and the exposure to tacrolimus and MPA was determined between 1 and 5 years post-transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 371 kidney transplant recipients were included in this study, of whom 56 developed a rejection episode after 12 months and 60 experienced graft failure after 5\u20137 years. No correlations were found between tacrolimus IPV or immunosuppression exposure and the number of donor-reactive cells after 5 years of transplantation. DSA were detected more often in patients with low exposure to both tacrolimus and MMF [4\/21 (19%) versus 17\/350 (4.9%), <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04]. In this cohort, neither tacrolimus IPV nor low overall immunosuppression exposure was associated with a higher incidence of rejection. However, regression analysis showed that a higher tacrolimus IPV was associated with an increased incidence of graft failure (odds ratio = 1.03, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study verifies the relationship between high tacrolimus IPV and impaired kidney allograft survival in long-term follow-up. DSA was also found to be more prevalent in patients with subtherapeutic concentrations of tacrolimus and MPA. An increased prevalence of donor-specific alloreactivity is yet to be demonstrated in patients with high IPV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000955","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T17:19:21Z","timestamp":1649438361000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes"],"prefix":"10.1097","volume":"44","author":[{"given":"Aleixandra","family":"Mendoza Rojas","sequence":"first","affiliation":[{"name":"Department of Internal Medicine\u2014Nephrology and Transplantation, Erasmus MC Transplantation Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;"},{"name":"Erasmus MC Transplant Institute, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\u2014Nephrology and Transplantation, Erasmus MC Transplantation Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;"},{"name":"Erasmus MC Transplant Institute, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"van Besouw","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\u2014Nephrology and Transplantation, Erasmus MC Transplantation Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;"},{"name":"Erasmus MC Transplant Institute, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Dieterich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\u2014Nephrology and Transplantation, Erasmus MC Transplantation Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;"},{"name":"Erasmus MC Transplant Institute, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronella","family":"de Kuiper","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\u2014Nephrology and Transplantation, Erasmus MC Transplantation Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;"},{"name":"Erasmus MC Transplant Institute, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla C.","family":"Baan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\u2014Nephrology and Transplantation, Erasmus MC Transplantation Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;"},{"name":"Erasmus MC Transplant Institute, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transpl."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant Rev."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/ajt.15346","article-title":"Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: a Collaborative Transplant Study Report","volume":"19","author":"S\u00fcsal","year":"2019","journal-title":"Am J Transpl."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"e13388","DOI":"10.1111\/petr.13388","article-title":"Intra-patient variability in tacrolimus exposure in pediatric liver transplant recipients: evolution, risk factors, and impact on patient outcomes","volume":"23","author":"Defrancq","year":"2019","journal-title":"Pediatr Transpl."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/tri.13726","article-title":"Association of graft survival with tacrolimus exposure and late intra-patient tacrolimus variability in pediatric and young adult renal transplant recipients-an international CTS registry analysis","volume":"33","author":"Gold","year":"2020","journal-title":"Transpl Int."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/ajt.13803","article-title":"High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients","volume":"16","author":"Vanhove","year":"2016","journal-title":"Am J Transpl."},{"key":"R7-20250603","first-page":"2","article-title":"A new method to calculate intra-patient variability in tacrolimus concentrations","volume":"29","author":"van Gelder","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/TP.0000000000003112","article-title":"From nonadherence to adherence","volume":"104","author":"Kuypers","year":"2020","journal-title":"Transplantation"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (COMMIT) group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"suppl 1","key":"R11-20250603","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/FTD.0000000000000287","article-title":"Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation","volume":"38","author":"Brunet","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1615\/CritRevImmunol.v22.i4.50","article-title":"Role of IFN-gamma in allograft rejection","volume":"22","author":"Hidalgo","year":"2002","journal-title":"Crit Rev Immunol."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/01.tp.0000264998.23349.54","article-title":"Interleukin-21: an interleukin-2 dependent player in rejection processes","volume":"83","author":"Baan","year":"2007","journal-title":"Transplantation"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fimmu.2016.00319","article-title":"The biological effects of IL-21 signaling on B-cell-mediated responses in organ transplantation","volume":"7","author":"Wu","year":"2016","journal-title":"Front Immunol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.humimm.2010.10.015","article-title":"Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells","volume":"72","author":"Parmigiani","year":"2011","journal-title":"Hum Immunol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2015.06.003","article-title":"Role of IL-21 signaling pathway in transplant-related biology","volume":"30","author":"Shi","year":"2016","journal-title":"Transpl Rev (Orlando)"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3389\/fimmu.2019.00748","article-title":"The number of donor-specific IL-21 producing cells before and after transplantation predicts kidney graft rejection","volume":"10","author":"van Besouw","year":"2019","journal-title":"Front Immunol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2021.04.011","article-title":"Donor-specific ELISPOT assay for predicting acute rejection and allograft function after kidney transplantation: a systematic review and meta-analysis","volume":"94","author":"Udomkarnjananun","year":"2021","journal-title":"Clin Biochem."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3389\/fimmu.2020.01972","article-title":"Immunosuppression has long-lasting effects on circulating follicular regulatory T cells in kidney transplant recipients","volume":"11","author":"Niu","year":"2020","journal-title":"Front Immunol."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"12445","DOI":"10.1038\/s41598-021-91967-w","article-title":"Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection","volume":"11","author":"Mendoza Rojas","year":"2021","journal-title":"Sci Rep."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3567","article-title":"Human memory T cells: generation, compartmentalization and homeostasis","volume":"14","author":"Farber","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/1744666X.2020.1693263","article-title":"Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients","volume":"15","author":"Mendoza Rojas","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","article-title":"Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development","volume":"100","author":"Rodrigo","year":"2016","journal-title":"Transplantation"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1681\/ASN.2017030287","article-title":"Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development","volume":"28","author":"Wiebe","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","author":"Davis","year":"2018","journal-title":"Am J Transpl."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transpl."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.3346\/jkms.2018.33.e217","article-title":"Characteristics and clinical significance of de novo donor-specific anti-HLA antibodies after kidney transplantation","volume":"33","author":"Jung","year":"2018","journal-title":"J Korean Med Sci."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12882-018-1014-2","article-title":"Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014","volume":"19","author":"Girerd","year":"2018","journal-title":"BMC Nephrol."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/petr.12637","article-title":"MC Minimum mycophenolic acid levels are associated with donor-specific antibody formation","volume":"20","author":"Filler","year":"2016","journal-title":"Pediatr Transpl."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-0012.2005.00261.x","article-title":"Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation","volume":"19","author":"Lederer","year":"2005","journal-title":"Clin Transpl."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O'Leary","year":"2016","journal-title":"Transplantation"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1432-2277.2012.01553.x","article-title":"Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week","volume":"25","author":"Barraclough","year":"2012","journal-title":"Transpl Int."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","article-title":"Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the Transplantation Society consensus meeting","volume":"25","author":"Le Meur","year":"2011","journal-title":"Transpl Rev (Orlando)"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fphar.2018.00908","article-title":"Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:15:45Z","timestamp":1748970945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000955","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"2021-09-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}